Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease
ConditionKartagener Syndrome
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of North Carolina, Chapel Hill
About this trial
The overall short-term goals of this project include the following: 1) identify the genes that are key to the function of respiratory cilia to protect the normal lung; and 2) the effects of genetic mutations that adversely affect ciliary function and cause primary ciliary dyskinesia (PCD), which results in life-shortening lung disease. The long-term goal of this project is to develop better understanding of the underlying genetic variability that adversely modifies ciliary function, and predisposes to common airway diseases, such as asthma and chronic obstructive pulmonary disease.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients who have a high suspicion for the diagnosis of PCD, based on clinical features
Disqualifiers
None
Trial population
Patients who have a high suspicion for the diagnosis of PCD, based on clinical features.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
1,800 Participants
are grouped into 1 trial groupGroup A: 1
Trial outcomes
Primary outcomes
1
This is not an interventional study
Not applicable. This is not an interventional study.
Time frame
This is not an interventional studySponsors and contacts
Click on the lead sponsor to view all of their trials.
University of North Carolina, Chapel Hill
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Source ClinicalTrials.gov